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Abstract
The availability of large healthcare datasets offers the opportunity for researchers to navigate
the traditional clinical and translational science research stages in a nonlinear manner. In
particular, data scientists can harness the power of large healthcare datasets to bridge from
preclinical discoveries (T0) directly to assessing population-level health impact (T4). A suc-
cessful bridge from T0 to T4 does not bypass the other stages entirely; rather, effective team
science makes a direct progression from T0 to T4 impactful by incorporating the perspectives
of researchers from every stage of the clinical and translational science research spectrum. In
this exemplar, we demonstrate how effective team science overcame challenges and, ulti-
mately, ensured success when a diverse team of researchers worked together, using healthcare
big data to test population-level substance use disorder (SUD) hypotheses generated from
preclinical rodent studies. This project, called Advancing Substance use disorder
Knowledge using Big Data (ASK Big Data), highlights the critical roles that data science
expertise and effective team science play in quickly translating preclinical research into public
health impact.
Introduction
The clinical and translational science research spectrum outlines how scientific discoveries in
the laboratory progress toward improved global health in distinct stages: basic scientific discov-
ery (T0), translation to humans (T1), translation to patients (T2), translation to practice (T3),
and translation to communities (T4) [1,2]. When the spectrum is navigated sequentially, dis-
coveries in the preclinical stage, oftentimes in animal studies, generate hypotheses that are sub-
sequently tested in small, well-controlled studies of humans [1]. These early human research
studies aim to establish proof of concept and safety before investing substantial resources in
large-scale studies [1]. When translating scientific research into communities, population-level
impact in real-world scenarios is oftenmeasured using very large healthcare datasets, i.e., health-
care big data [1,3].
The translational science research spectrum does not have to be navigated linearly, though
[4]. The availability and accessibility of healthcare big data offers an emerging opportunity to
rethink the traditional approach to discovery [3]. As healthcare big data are now more acces-
sible, investigators are frequently incorporating these data resources to investigate hypotheses
generated in preclinical studies. When the study is ethically impractical or cost-prohibitive in
clinical stages, this strategy has a distinct advantage. The data management and analytics tasks
required for working with healthcare big data in T4 fall primarily to data scientists [3]. However,
it is the successful, integrative collaboration between data scientists and researchers from every
stage of the translational science research spectrum that ensures that the data-related tasks in T4
are comprehensive and performed in such a way to ensure that the end discovery is an impactful
translation [5,6].
Here, we present the exemplar of a research study initiated at the University of Kentucky
called Advancing Substance use disorder Knowledge with Big Data (ASK Big Data). The
ASK Big Data project is a prime example of how big data may help shape the translational sci-
ence research paradigm (T0 directly to T4), as shown in Fig. 1. The experiences of the ASK Big
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Data team highlight the importance of effective team science as a
means to overcoming common challenges faced by data scientists
on projects that circumvent the implementation of some stages of
the translational science research spectrum. In this paper, we first
provide a brief summary of the ASK Big Data team’s relevant
research findings in order to give context to the discussion of les-
sons learned in the effort to bridge preclinical findings to big data
discovery.
Motivation
Attention-deficit/hyperactivity disorder (ADHD) is a prevalent
neurodevelopmental disorder, estimated in 2015–2016 to affect
10.2% of children and adolescents aged 4–17 years old in the
USA [7]. Estimated at only 6.1% in 1997–1998, the prevalence
of ADHD in children and adolescents has increased significantly
over the 20-year span both overall and in subgroups defined
by age, sex, race/ethnicity, family income, and geographic
region [7]. As the rate of ADHD diagnoses has increased, so has
the rate of medication use for treating ADHD [8,9]. As of 2010,
74% of children and adolescents with ADHD were taking medica-
tion to treat the disorder [10].
Substance use disorder (SUD), resulting from recurrent,
compulsive drug or alcohol use despite harmful consequence,
is also a major public health concern in the USA, affecting
approximately 20.3 million Americans aged 12 or older in
2018 [11]. SUD and ADHD are highly comorbid; adults with
a history of ADHD are twice as likely to develop SUD compared
to adults without ADHD [12,13]. There is some evidence that
medication for ADHD contributes to the link between ADHD
and SUD, but the biological mechanism by which this occurs
is not well known [14–20]. Prior studies of ADHD medication
initiation in children have found no evidence of increased risk
[14–17] or even a decreased risk [18] for developing SUD later
in life. In contrast, there is emerging evidence that when the ini-
tiation of ADHDmedication occurs during adolescence, there is
an increased risk of developing SUD [14,19]. Adolescence is a
particularly important period for the development of brain
structure and function, so it is possible that adolescents may
be particularly sensitive to pharmacological changes during this
time [20]. These diverging results motivated the desire to better
understand how the timing of initiating treatment for ADHD
during adolescence is linked to subsequent SUD in a well-
controlled setting.
Basic Scientific Discovery (T0)
To examine the underlying biological mechanisms and impact of
treatment for ADHD in preclinical studies, experiments can be
performed on rats that exhibit the ADHD phenotype (spontane-
ously hypertensive rats) and on rats that do not exhibit the
ADHD phenotype (Wistar–Kyoto and Wistar rats) [21]. A num-
ber of rodent experiments were performed in the labs of the basic
science researchers on our team to explore the effects of ADHD
medication on the rats’ propensity to exhibit addiction-like behav-
ior [22–27]. In one rodent study, rats exhibiting the ADHD
phenotype were givenmethylphenidate, a popular stimulant medi-
cation used to treat ADHD in humans, starting at the beginning of
their adolescent period [22]. After receiving methylphenidate
treatment throughout adolescence, these rats acquired cocaine
self-administration faster and showed greater motivation to self-
administer cocaine as compared to rats receiving vehicle (no
ADHD medication) and as compared to rats not exhibiting the
ADHD phenotype that received methylphenidate [22].
Several subsequent rodent studies were performed to explore
additional aspects of the relationship between ADHD medication
initiation during adolescence and future susceptibility to cocaine
addiction. Extending treatment into adulthood did not diminish
the greater risk of cocaine self-administration in rats exhibiting
the ADHD phenotype with adolescent-initiated methylphenidate
[23]. However, the type of ADHD medication did appear to be an
important factor, as vulnerability to cocaine addiction was not fur-
ther elevated in these rats when treated during adolescence with
atomoxetine or d-amphetamine [24–27]. Details of the experimen-
tal methodologies and results from these rodent studies are pub-
lished elsewhere [22–27]. Altogether, these preclinical findings
led to the basic scientists’ hypothesis that adolescence is a sensitive
period for initiation of ADHDmedication, which may increase the
risk for SUD in adulthood.
Translation to Humans, Patients, and Practice (T1–T3)
Translating our team’s preclinical findings into humans in a ran-
domized controlled trial was not possible due to the ethical limi-
tations of assigning the type and timing of ADHD medications.
The time and costs required for conducting a randomized con-
trolled trial presented further difficulties. Other groups have initi-
ated observational studies to test similar hypotheses about ADHD
medication and SUD in humans, with varied results. One study
found evidence that the risk of adolescent SUD was higher among
those who initiated ADHD medication during adolescence
Fig. 1. Clinical and translational science research spectrum.
Note: The clinical and translational science research spectrum can be navigated sequentially (solid line). The Advancing Substance use disorder Knowledge using Big Data
(ASK Big Data) project demonstrates one way in which these stages can be navigated in a nonlinear fashion (dashed line).
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(vs. early childhood) and among those using only non-stimulant
medications (vs. stimulant medications), but this study was limited
by the cross-sectional nature of data collection [28]. Another study
did use temporal ADHD treatment records from large healthcare
claims data, and it found evidence that ADHD medication was
associated with lower concurrent risk of SUD [29]. However, this
study included a heterogeneous population of adolescents and
adults (aged 13–64 years) and did not specifically explore the
initiation and patterns of ADHD medication prescribing among
adolescents [29].
A more focused study using temporal data was needed to spe-
cifically address the hypotheses generated in preclinical studies
regarding ADHD medication timing in adolescence and sub-
sequent risk of SUD. The basic scientists responsible for the afore-
mentioned rodent studies at the University of Kentucky and
Boston University wanted to be able to address potential latent fac-
tors encoded in complex medication use patterns that can only be
studied using temporal healthcare big data. They knew that it was
necessary to collaborate with data scientists to accomplish this goal
of jumping directly to T4, and through this undertaking, the ASK
Big Data team formed (Table 1).
Translation to Population Health (T4)
To investigate the link between timing of ADHDmedication in ado-
lescence and subsequent risk of SUD on a population level, the ASK
Big Data team utilized the IBM (formerly Truven Health Analytics)
MarketScan Commercial Claims and Encounters database (referred
to hereafter as IBM MarketScan) [31]. The IBM MarketScan data-
base includes inpatient and outpatient medical encounter data as
well as prescription drug information from Americans with
employer-sponsored private health insurance and their dependents.
Using the International Classification of Disease (ICD-9) diagnosis
codes, the ASK Big Data team extracted all ADHD-related records
from the IBM MarketScan database between January 2009 and
December 2015 [31]. In total, 11,778,912 records were extracted,
including information from 118,063 enrollees with adolescent
(13–20 years) initiation of ADHD medication [31]. In addition to
temporal data from longitudinal ADHD medication records, the
extracted data also included stationary features such as sex,
ADHD initiation age, and medication type [31]. Among the
118,063 enrollees with adolescent initiation of ADHD medication,
9376 (7.9%) were classified as ADHD-SUD positive, defined as
being diagnosed with SUD for the first time after having an
ADHD medication prescription for at least 5 months [31].
To predict SUD using the temporal ADHDmedication records,
the ASK Big Data team utilized a long short-termmemory (LSTM)
model which is a type of recurrent neural network that accommo-
dates longitudinal data [31]. Further details regarding specification
of the LSTM models can be found in Fouladvand et al. [31]. Using
the adolescent temporal ADHD medication records from IBM
MarketScan, the LSTM model was able to predict SUD with an
accuracy of 0.84 (F1 score= 0.82 ± 0.01) [31]. The high perfor-
mance of the LSTM model relative to traditional classification
models (random forest accuracy = 0.60, support vector machine
accuracy = 0.56) indicates that there may be critical latent factors
in the detailed temporal data that capture the relationship between
ADHD medication prescribing and subsequent SUD in adoles-
cents [31]. In addition to the temporal data, the ASK Big Data team
also explored whether stationary features such as age, sex, and
medication types in the IBM MarketScan data aided in the detec-
tion of SUD among adolescents being treated for ADHD [31]. To
summarize the results of Fouladvand et al., temporal features of
ADHDmedication prescribing such as gaps and duration of medi-
cation, rather than stationary features such as demographics, were
the important factors in predicting the development of SUD
among adolescent initiators of ADHD medication [31].
Overall, these findings supported population-level investigation
of the hypothesis generated in T0 that the adolescent period is a
sensitive time for initiation of ADHD medication as it relates to
development of SUD. Moreover, these data discoveries have high-
lighted the need to iteratively identify and refine clinically-mean-
ingful SUD phenotypes with domain expertise. Considering the
trajectory of experiences leading to SUDwith population-level data
continues to be an active research program for the ASK Big Data
team. With knowledge from preclinical findings and data-driven
discoveries, our approach continues to provide novel opportunities
to investigate relationships between life course exposures and SUD.
The ASK Big Data team’s approach leveraged big population-level
healthcare claims data to confirm that temporal ADHD
Table 1. Translational data science team for the ASK Big Data project
Investigator Expertise Center for Clinical and Translational Science Role
Biomedical informatician (MPI) Ontology and terminology systems; T4 Director, Biomedical Informatics
Biomedical informatician, (MPI) Population (SUD) outcomes and policy; T4 Director, Biomedical Informatics
Neuropharmacologist, (MPI) SUD research, drug discovery; T0–T1 Director, Drug Discovery and Development
Behavioral neuroscientist SUD research, drug discovery; T0
Biomedical informatician Natural language processing, computational data science; T4
Biostatistician Population data, secondary data analysis and design; T0–T4 Co-Director, BERD
Biostatistician Population data, causal inference; T0–T4 BERD
Clinical pharmacist SUD research, pharmacy practice; T2–T4
Clinician Pediatric psychiatry, ADHD, SUD research; T2–T4
NIH National Center for Advancing Translational Sciences (NCATS) and the Clinical and Translational Science Award (CTSA) programs are particularly good environments for connecting
researchers across the translational science research spectrum [30]. The role of the Center for Clinical and Translational Science at the University of Kentucky is evident in the ASK Big Data team.
ASK Big Data, advancing substance use disorder knowledge with big data; MPI, multiple principal investigator; SUD, substance use disorder; BERD, biostatistics, epidemiology, and research
design core; ADHD, attention-deficit/hyperactivity disorder.
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medication prescribing records can be used to predict subsequent
SUD in adulthood. The findings from these initial outcomes con-
tinue to generate new avenues for research and continue to offer
this team an innovative strategy for exploring drivers (precursors
and exposures) of SUD experience.
Lessons Learned
The ASK Big Data team first started taking shape as one of the key
investigators on the ADHD rodent studies, a basic scientist with a
background in pharmacology, wanted to see if and how findings
from animal studies might translate to humans. The features of
these experiments would be unethical to conduct in humans,
and the time period to observe similar life stages in humans would
be cost-prohibitive. The pharmacologist teamed up with two
biomedical informaticians, one with expertise in health policy and
one with expertise in computational data science. Their primary
objective was to determine if patient experiences encoded in big data
would provide human health evidence for these preclinical trends.
This established the T0 and T4 pillars of the ASK Big Data team,
with researchers from both ends of the translational science research
spectrum serving as principal investigators on the project. Rather
than having a single principal investigator, this multiple principal
investigator approach ensured that no one side (domain leader or
data scientist) felt stronger ownership over the project than another.
However, even with expertise on both ends of the translational sci-
ence research spectrum, jumping from T0 to T4 is not a trivial task.
In fact, this exemplar offers insight into four key attributes of an
effective team when attempting to bridge and integrate elements
of the translational research spectrum.
Lesson 1: Recognize that everyone is an expert and a novice
While research teams are often constructed based on expertise, the
ASK Big Data team was comprised of investigators of similar rank,
holding leadership positions, with experience as principal investi-
gators. As such, each person was recognized as an expert in their
field but had gaps in knowledge related to this research project. For
example, preclinical scientists were less familiar with population-
level data, SUD (clinical or preclinical) research was not a domain
area of expertise for all, and data science methodology was not a
standard analytic approach for secondary data analysis. The con-
trast of high levels of expertise in one area with relative naiveté in
another resulted in an equalizing effect. All researchers capably
contributed as experts but benefited in learning from each other.
Further, this reliance on each other for information created a foun-
dation of trust throughout the team. A hallmark of team meetings
was to remain on a topic until everyone had an understanding; no
researcher was left behind, and no question was unwelcome.While
this was not always expeditious, the efforts to impress or demon-
strate superior roles that sometimes occur in teams did not arise.
Lesson 2: Avoid the divide-and-conquer approach
Often teams will divide the work that needs to be completed for
efficiency. For example, in an effort to save a biostatistician’s time,
an investigator may provide parts of a proposal and ask for the
methods section to be written. Many teams work within product
or function structures where like groups work together on similar
parts [32]. This style of team organization requires the principal
investigator to act as coordinator or lead to converge the different
components. In scientific research, this division of effort often
occurs to complete sections of a manuscript or components of a
proposal; pieces created individually are then circulated among
all. The ASK Big Data team used a less common approach of a flat
organizational structure, where investigators work at the same level
and as a collective. One of the unique features of the ASK Big Data
teamwas tomeet together and write or work through problems as a
group, i.e., “group write”. This type of integrated work style con-
tributed to shared ownership of research products, made possible
by the open exchange of ideas and concepts (see Lesson 1). Data
scientists were not relegated only to “their” sections, and preclinical
investigators did not shirk away for the methodological details.
This unique approach circumvented typical clashes between
personalities because efforts were so intertwined.
A critical factor for success on the ASK Big Data team was that
every member of the team was deeply invested in the project. None
of the team members acted as consultants; rather, the basic scien-
tists, clinicians, pharmacists, biostatisticians, informaticians, and
computational data scientists were all at the table to contribute
their unique perspective. It quickly became obvious how important
this personal investment was for the ASK Big Data team. Even
when just one team member was absent from a meeting, it was
not uncommon for the team to head in a direction that later
had to be rerouted when the full team next assembled. While this
provides a feature for successful team science that can create an
exciting learning experience, it does require a willingness and abil-
ity to stretch into other disciplines. A biostatistician who does not
embrace the domain area or the investigator who considers meth-
odology as technical details cannot successfully engage in this type
of structure.
Lesson 3: Embrace discipline-specific approaches to science
Although there was significant exchange and shared learning in the
ASK Big Data team, the span across the translational science spec-
trum identified stark differences in how T0 and T4 researchers
view the process of scientific inquiry. Basic scientists who primarily
work in the T0 stage are accustomed to testing very specific
hypotheses with scientifically-rigorous, well-controlled studies.
On the other hand, computational data scientists who spend most
of their time in the T4 stage are comfortable using complex meth-
ods to extract information frommessy data that are often collected
for a primary purpose not related to research. The existence of
these very different but both valuable philosophies for conducting
scientific research can lead to discord between the approaches of
basic science and computational data science. Biostatistics played
a key role in bridging this gap to avoid discord on the ASK Big Data
team. Since biostatisticians typically have some experience with
both approaches to scientific research, they are uniquely suited
to facilitate interactions between basic scientists and computa-
tional data scientists. For example, data discoveries in the ASK
Big Data project were improved by specifically defining risk sets
and control groups; appropriately framing the temporal sequence
of events within health records increased the validity of the find-
ings. With data as the connector, biostatistics provided a common
framework for discussing analytic plans and strategizing about
how to utilize, interpret, and present the results.
Lesson 4: Frame data discovery in a clinical context
Translation of T0–T4 requires the population-level data science in
T4 to be performed in a clinically-appropriate andmeaningful way.
In other words, T1, T2, and T3 are relevant and necessary even if
the research process does not formally incorporate these stages.
Incorporating perspectives from experts across the translational
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research spectrumwas paramount to overcoming this challenge on
the ASK Big Data project. For example, the enrollee medication
record matrix in the IBM MarketScan data consisted of 0/1 values
where rows are visits and columns are medications [31]. This poses
a challenge for data scientists because these types ofmatrices can be
quite sparse, and a high degree of data sparsity can lower the per-
formance of a deep learning model [33]. Key members of the ASK
Big Data team provided clinical expertise to help overcome this
challenge. For example, the clinician was able to shed light on
how diagnosis codes are entered, which informed the team’s def-
inition of the SUD outcome in the IBM MarketScan data. The
pharmacist provided practical information on how ADHD medi-
cation is prescribed, such as the common 3-month gap in medica-
tion observed in many adolescents due to summer break in the
school year. Taking these perspectives into account, the ASK Big
Data team’s data scientists were able to reduce data sparsity by
removing four types of records: (1) all empty records before the
first ADHD medication prescription, (2) all empty records after
the last ADHD medication prescription, (3) sequences in which
the enrollee used ADHD medication for less than 5 months,
and (4) enrollees who started using ADHD medication less than
5 months before being diagnosed with SUD [31]. While the data
sparsity issue was identified by the team’s computational data sci-
entists, developing an appropriate solution required input from
other ASK Big Data team members who had intimate knowledge
of ADHDmedication prescribing in practice. Engaging researchers
from all stages of the translational science research spectrum
embedded T1–T3 principles and expertise within the process
and expanded the domain expertise of the data scientists on the
ASK Big Data team, offering the perspective needed to implement
an appropriate analysis.
Conclusion
Effective team science requires a diversity of thought and true inte-
gration across disciplines [5,6]. The ASK Big Data team demon-
strated this not only by recruiting a highly interdisciplinary
team of researchers representing every stage of the translational
science research spectrum, but also by ensuring that each of these
team members had an equally important seat at the table, with
everyone at the table equally engaged.
Navigating the translational science research spectrum sequen-
tially can be time-consuming, expensive, and potentially unethical,
and translating preclinical discoveries into humans is particularly
prone to failure [34]. Creating a pathway directly from preclinical
work to analyzing population-level impact circumvents these chal-
lenges. Data scientists should feel empowered by the accessibility of
healthcare big data in making this pathway viable. When navigat-
ing this streamlined approach, impactful research in T4 cannot be
made by data scientists alone. Working effectively with researchers
from every stage of the clinical and translational science research
spectrum ensures that data scientists ask questions and design
analyses and data discovery strategies that are appropriate in the
context of clinical practice.
This case study should not be viewed as a call for abandonment
of the traditional progress through clinical and translational sci-
ence research stages; each of these stages is certainly necessary
for processes like drug development. Instead, we use the ASK
Big Data project to demonstrate one of many ways that data sci-
ence alters and augments the paradigm. In this example, we present
an alternative pathway, but data science can also serve to make
these pathways bidirectional. We fully expect that the SUD
research community can benefit from testing data-discovered
hypotheses within preclinical or clinical studies. Our experience
demonstrates how team science and, consequently, translational
data science, can overcome common challenges for investigators
as T0–T4 expertise is integrated to include preclinical, clinical,
informatics, and biostatistics to solve complex, global human
health problems.
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